Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...
Nerandomilast is an oral, preferential PDE4B inhibitor approved in China for the treatment of adult patients with IPF and PPF. It was also approved by the U.S. Food and Drug Administration (FDA) for ...
CNW/ - BirchBioMed Inc., a leading clinical stage biopharmaceutical company, expert in the development of products for ...
When breathing becomes increasingly difficult with no clear explanation, idiopathic pulmonary fibrosis (IPF) might be the culprit behind the concerning symptoms. This rare yet devastating lung disease ...
UVA Health lung researchers are developing a promising approach to detecting patients at risk of interstitial lung disease (ILD), an increasingly common condition that is a leading reason for lung ...
Idiopathic pulmonary fibrosis stands as one of medicine’s most challenging respiratory conditions, gradually transforming healthy lung tissue into stiff, scarred material that severely compromises ...
The long-term effects of respiratory viral infections such as COVID-19 are a major public health burden. Some estimates suggest over 65 million people around the world suffer from long COVID-19.
For patients affected by lung diseases such as pulmonary fibrosis, chronic obstructive pulmonary disease, cystic fibrosis and others, cures for their diseases are incredibly rare, if not nonexistent. ...
Pulmonary sarcoidosis is a condition that causes tiny groups of immune cells to clump in your lungs. These groups of cells form swollen, inflamed lumps called granulomas. Granulomas can make it hard ...
Researchers have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback